Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fibromyalgia Trial Endpoints Should Be Validated In Real Time – FDA Cmte.

Executive Summary

Endpoints of fibromyalgia efficacy trials should be validated in "real time" with pain as one of the primary outcome measures, FDA's Arthritis Advisory Committee recommended June 23

You may also be interested in...



Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim

The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia

Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim

The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia

Cymbalta Finds Divergent FDA, European Standards For Fibromyalgia Approval

The stance of U.S and European regulators on fibromyalgia drug development is diverging, as Lilly has discovered in pursuing a fibromyalgia claim for Cymbalta (duloxetine).

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel